cosmofer
pharmacosmos a/s - geležis (iii) - injekcinis ar infuzinis tirpalas - 50 mg/ml - iron, parenteral preparations
cosmofer
lex ano, uab - geležis (iii) - injekcinis ar infuzinis tirpalas - 50 mg/ml - iron, parenteral preparations
mekinist
novartis europharm limited - trametinibas - melanoma - antinavikiniai vaistai - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ir 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. nesmulkialąstelinio plaučių vėžio (nsclc)trametinib kartu su dabrafenib fluorouracilu ir folino suaugusių pacientų su papildoma nesmulkialąstelinio plaučių vėžio su braf v600 mutacija.
isturisa
recordati rare diseases - osilodrostat fosfatas - cushingo sindromas - kortikosteroidų sisteminis naudoti - isturisa fluorouracilu ir folino endogeninio kušingo sindromas, suaugusiems.
jakavi
novartis europharm limited - ruksolitinibas (fosfatas) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antinavikiniai vaistai - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi fluorouracilu ir folino suaugusių pacientų su polycythaemia vera, kurie yra atsparūs arba netoleruoja hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
diclofenaco kern pharma
actiofarma, uab - diklofenakas - gelis - 11,6 mg/g - diclofenac
aciclovir kern pharma
actiofarma, uab - acikloviras - kremas - 50 mg/g - aciclovir
desloratadina kern pharma
lex ano, uab - desloratadinas - plėvele dengtos tabletės - 5 mg - desloratadine
acido alendronico semanal kern pharma
lex ano, uab - alendrono rūgštis - tabletės - 70 mg - alendronic acid
naloxona kern pharma
lex ano, uab - naloksono hidrochloridas - injekcinis ar infuzinis tirpalas - 0,4 mg/ml - naloxone